{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:26:15Z","timestamp":1790108775291,"version":"4.0.1"},"reference-count":181,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007301","name":"Harvard University Center for AIDS Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008374","name":"Center for AIDS Research, Emory University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005294","name":"Massachusetts General Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005294","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.idc.2019.05.004","type":"journal-article","created":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T04:33:18Z","timestamp":1561609998000},"page":"707-742","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Management of Virologic Failure and HIV Drug Resistance"],"prefix":"10.1016","volume":"33","author":[{"given":"Suzanne M.","family":"McCluskey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Siedner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent C.","family":"Marconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.idc.2019.05.004_bib1","unstructured":"Joint United Nations Programme on HIV\/AIDS. 90-90-90: an ambitious treatment target to help end the AIDS epidemic. 2014."},{"key":"10.1016\/j.idc.2019.05.004_bib2","series-title":"HIV in the United States","author":"Centers for Disease Control","year":"2018"},{"issue":"47","key":"10.1016\/j.idc.2019.05.004_bib3","first-page":"1113","article-title":"Vital Signs: HIV diagnosis, care, and treatment among persons living with HIV--United States, 2011","volume":"63","author":"Bradley","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"10.1016\/j.idc.2019.05.004_bib5","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S1473-3099(17)30681-3","article-title":"Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study","volume":"18","author":"Hermans","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2019.05.004_bib6","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3851\/IMP2949","article-title":"Risk of virological failure in HIV-1-infected patients experiencing low-level viraemia under active antiretroviral therapy (ANRS C03 cohort study)","volume":"20","author":"Vandenhende","year":"2015","journal-title":"Antivir Ther"},{"issue":"10","key":"10.1016\/j.idc.2019.05.004_bib7","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/cid\/cit529","article-title":"Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation","volume":"57","author":"Laprise","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.idc.2019.05.004_bib8","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1001\/jama.293.7.817","article-title":"Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART","volume":"293","author":"Nettles","year":"2005","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.idc.2019.05.004_bib9","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1086\/496985","article-title":"Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis","volume":"41","author":"Sungkanuparph","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"9171","key":"10.1016\/j.idc.2019.05.004_bib10","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/S0140-6736(98)12291-2","article-title":"Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial","volume":"353","author":"Durant","year":"1999","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.idc.2019.05.004_bib11","doi-asserted-by":"crossref","first-page":"F83","DOI":"10.1097\/00002030-200006160-00001","article-title":"A\u00a0randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS","volume":"14","author":"Baxter","year":"2000","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.idc.2019.05.004_bib12","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00002030-200202150-00008","article-title":"Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA)","volume":"16","author":"Cingolani","year":"2002","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.idc.2019.05.004_bib13","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00002030-200201250-00010","article-title":"Clinical utility of HIV-1 genotyping and expert advice: the Havana trial","volume":"16","author":"Tural","year":"2002","journal-title":"AIDS"},{"issue":"7","key":"10.1016\/j.idc.2019.05.004_bib14","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1177\/135965350601100711","article-title":"A\u00a0randomized controlled trial of genotypic HIV drug resistance testing in HIV-1-infected children: the PERA (PENTA 8) trial","volume":"11","author":"Green","year":"2006","journal-title":"Antivir Ther"},{"issue":"4","key":"10.1016\/j.idc.2019.05.004_bib15","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/00002030-200203080-00009","article-title":"A\u00a0randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy","volume":"16","author":"Cohen","year":"2002","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.idc.2019.05.004_bib16","first-page":"295","article-title":"A\u00a0randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575","volume":"19","author":"Haubrich","year":"2005","journal-title":"AIDS"},{"issue":"5","key":"10.1016\/j.idc.2019.05.004_bib17","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/00002030-200203290-00008","article-title":"Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial","volume":"16","author":"Meynard","year":"2002","journal-title":"AIDS"},{"issue":"5","key":"10.1016\/j.idc.2019.05.004_bib18","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1086\/381266","article-title":"Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trial","volume":"38","author":"Wegner","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2019.05.004_bib19","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/00126334-200303010-00005","article-title":"Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial","volume":"32","author":"Mazzotta","year":"2003","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"6","key":"10.1016\/j.idc.2019.05.004_bib20","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/135965350300800604","article-title":"Phenotype or virtual phenotype for choosing antiretroviral therapy after failure: a prospective, randomized study","volume":"8","author":"Perez-Elias","year":"2003","journal-title":"Antivir Ther"},{"issue":"5","key":"10.1016\/j.idc.2019.05.004_bib21","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/01.qai.0000148533.12329.96","article-title":"A\u00a0randomized controlled trial of the value of phenotypic testing in addition to genotypic testing for HIV drug resistance: evaluation of resistance assays (ERA) trial investigators","volume":"38","author":"Dunn","year":"2005","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"6","key":"10.1016\/j.idc.2019.05.004_bib22","doi-asserted-by":"crossref","first-page":"440","DOI":"10.7326\/0003-4819-134-6-200103200-00008","article-title":"Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness","volume":"134","author":"Weinstein","year":"2001","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.idc.2019.05.004_bib23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/135965350400900106","article-title":"Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV","volume":"9","author":"Corzillius","year":"2004","journal-title":"Antivir Ther"},{"issue":"9","key":"10.1016\/j.idc.2019.05.004_bib24","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1086\/496984","article-title":"Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis","volume":"41","author":"Sax","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.idc.2019.05.004_bib25","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1468-1293.2007.00491.x","article-title":"The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach","volume":"8","author":"Yazdanpanah","year":"2007","journal-title":"HIV Med"},{"issue":"1","key":"10.1016\/j.idc.2019.05.004_bib26","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1371\/journal.pone.0000173","article-title":"Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure","volume":"2","author":"Sendi","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.idc.2019.05.004_bib27","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1758-2652-14-24","article-title":"The net cost of incorporating resistance testing into HIV\/AIDS treatment in South Africa: a Markov model with primary data","volume":"14","author":"Rosen","year":"2011","journal-title":"J\u00a0Int AIDS Soc"},{"issue":"4","key":"10.1016\/j.idc.2019.05.004_bib28","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/cid\/cis887","article-title":"The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa","volume":"56","author":"Levison","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.idc.2019.05.004_bib29","doi-asserted-by":"crossref","first-page":"e109148","DOI":"10.1371\/journal.pone.0109148","article-title":"Cost-effectiveness of HIV drug resistance testing to inform switching to second line antiretroviral therapy in low income settings","volume":"9","author":"Phillips","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.idc.2019.05.004_bib30","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/QAI.0000000000000426","article-title":"Cost-effectiveness of genotype testing for primary resistance in Brazil","volume":"68","author":"Luz","year":"2015","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"8","key":"10.1016\/j.idc.2019.05.004_bib31","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/cid\/cix542","article-title":"Should we be testing for baseline integrase resistance in patients newly diagnosed with human immunodeficiency virus?","volume":"65","author":"Koullias","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2019.05.004_bib32","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1016\/S2352-3018(17)30190-X","article-title":"Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study","volume":"5","author":"Phillips","year":"2018","journal-title":"Lancet HIV"},{"issue":"2","key":"10.1016\/j.idc.2019.05.004_bib33","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/cid\/ciy463","article-title":"Human immunodeficiency virus drug resistance: 2018 recommendations of the International Antiviral Society-USA Panel","volume":"68","author":"Gunthard","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"18","key":"10.1016\/j.idc.2019.05.004_bib34","doi-asserted-by":"crossref","first-page":"F123","DOI":"10.1097\/00002030-199912240-00001","article-title":"Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy","volume":"13","author":"Devereux","year":"1999","journal-title":"AIDS"},{"issue":"18","key":"10.1016\/j.idc.2019.05.004_bib35","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1097\/00002030-199912240-00007","article-title":"Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype","volume":"13","author":"Verhofstede","year":"1999","journal-title":"AIDS"},{"issue":"11","key":"10.1016\/j.idc.2019.05.004_bib36","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1086\/503914","article-title":"Web resources for HIV type 1 genotypic-resistance test interpretation","volume":"42","author":"Liu","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2019.05.004_bib37","series-title":"Algorithm for the use of genotypic HIV-1 resistance data (version Rega v10.0.0)","author":"Camacho","year":"2017"},{"key":"10.1016\/j.idc.2019.05.004_bib38","author":"Agence National de Recerche sur le SIDA (ANRS)"},{"issue":"2","key":"10.1016\/j.idc.2019.05.004_bib39","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000331999","article-title":"HIV-GRADE: a publicly available, rules-based drug resistance interpretation algorithm integrating bioinformatic knowledge","volume":"55","author":"Obermeier","year":"2012","journal-title":"Intervirology"},{"key":"10.1016\/j.idc.2019.05.004_bib40","unstructured":"Available at: https:\/\/www.iasusa.org\/wp-content\/uploads\/2018\/01\/2017hiv-muta-article.pdf. Accessed January 4, 2019."},{"issue":"4","key":"10.1016\/j.idc.2019.05.004_bib41","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/09540120410001683402","article-title":"Predictors of antiretroviral adherence","volume":"16","author":"Murphy","year":"2004","journal-title":"AIDS Care"},{"issue":"1","key":"10.1016\/j.idc.2019.05.004_bib42","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2105\/AJPH.2015.302905","article-title":"Housing status, medical care, and health outcomes among people living with HIV\/AIDS: a systematic review","volume":"106","author":"Aidala","year":"2016","journal-title":"Am J Public Health"},{"issue":"3","key":"10.1016\/j.idc.2019.05.004_bib43","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1007\/s10461-017-1808-4","article-title":"The impact of substance use on adherence to antiretroviral therapy among HIV-infected women in the United States","volume":"22","author":"Zhang","year":"2018","journal-title":"AIDS Behav"},{"issue":"5","key":"10.1016\/j.idc.2019.05.004_bib44","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/1055329003261981","article-title":"Stigma: a health barrier for women with HIV\/AIDS","volume":"15","author":"Carr","year":"2004","journal-title":"J\u00a0Assoc Nurses AIDS Care"},{"issue":"5","key":"10.1016\/j.idc.2019.05.004_bib45","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10461-006-9106-6","article-title":"The role of HIV serostatus disclosure in antiretroviral medication adherence","volume":"10","author":"Stirratt","year":"2006","journal-title":"AIDS Behav"},{"issue":"11","key":"10.1016\/j.idc.2019.05.004_bib46","doi-asserted-by":"crossref","first-page":"817","DOI":"10.7326\/0003-4819-156-11-201206050-00419","article-title":"Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel","volume":"156","author":"Thompson","year":"2012","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.idc.2019.05.004_bib47","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1089\/108729103771928690","article-title":"Psychiatric and social barriers to HIV medication adherence in a triply diagnosed methadone population","volume":"17","author":"Palmer","year":"2003","journal-title":"AIDS Patient Care STDS"},{"issue":"4","key":"10.1016\/j.idc.2019.05.004_bib48","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1086\/596482","article-title":"Better adherence with once-daily antiretroviral regimens: a meta-analysis","volume":"48","author":"Parienti","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2019.05.004_bib49","series-title":"Global action plan on HIV drug resistance 2017-2012: 2018 progress report","author":"World Health Organization","year":"2018"},{"key":"10.1016\/j.idc.2019.05.004_bib50","author":"University of Liverpool"},{"issue":"4","key":"10.1016\/j.idc.2019.05.004_bib51","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1177\/0091270006298603","article-title":"The effect of different meal types on the pharmacokinetics of darunavir (TMC114)\/ritonavir in HIV-negative healthy volunteers","volume":"47","author":"Sekar","year":"2007","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.idc.2019.05.004_bib52","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2165\/00003088-200544100-00003","article-title":"Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir","volume":"44","author":"Le Tiec","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.idc.2019.05.004_bib53","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/jcph.210","article-title":"Effect of food on rilpivirine\/emtricitabine\/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infection","volume":"54","author":"Custodio","year":"2014","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.idc.2019.05.004_bib54","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.2169\/internalmedicine.48.1906","article-title":"Successful absorption of antiretroviral drugs after gastrojejunal bypass surgery following failure of therapy through a jejunal tube","volume":"48","author":"Kamimura","year":"2009","journal-title":"Intern Med"},{"issue":"1","key":"10.1016\/j.idc.2019.05.004_bib55","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1590\/S1413-86702003000100003","article-title":"AIDS-associated diarrhea and wasting in Northeast Brazil is associated with subtherapeutic plasma levels of antiretroviral medications and with both bovine and human subtypes of Cryptosporidium parvum","volume":"7","author":"Brantley","year":"2003","journal-title":"Braz J Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2019.05.004_bib56","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1097\/01.qai.0000245887.58886.ac","article-title":"Sustained benefit from a long-term antiretroviral adherence intervention. Results of a large randomized clinical trial","volume":"43","author":"Mannheimer","year":"2006","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"9","key":"10.1016\/j.idc.2019.05.004_bib57","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/cid\/ciu046","article-title":"Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials","volume":"58","author":"Nachega","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2019.05.004_bib58","series-title":"HIV drug resistance report","author":"World Health Organization","year":"2017"},{"issue":"4","key":"10.1016\/j.idc.2019.05.004_bib59","doi-asserted-by":"crossref","first-page":"e1001810","DOI":"10.1371\/journal.pmed.1001810","article-title":"Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis","volume":"12","author":"Rhee","year":"2015","journal-title":"PLoS Med"},{"issue":"3","key":"10.1016\/j.idc.2019.05.004_bib60","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1473-3099(17)30702-8","article-title":"HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis","volume":"18","author":"Gupta","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.1016\/j.idc.2019.05.004_bib61","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1089\/aid.2017.0295","article-title":"Changes from 2000 to 2009 in the prevalence of HIV-1 containing drug resistance-associated mutations from antiretroviral therapy-naive, HIV-1-infected patients in the United States","volume":"34","author":"Ross","year":"2018","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"7","key":"10.1016\/j.idc.2019.05.004_bib62","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1089\/apc.2018.0020","article-title":"Increasing prevalence of HIV pretreatment drug resistance in women but not men in rural uganda during 2005-2013","volume":"32","author":"McCluskey","year":"2018","journal-title":"AIDS Patient Care STDS"},{"issue":"7","key":"10.1016\/j.idc.2019.05.004_bib63","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1093\/jac\/dkv049","article-title":"HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007-12: impact on susceptibility to first-line strategies","volume":"70","author":"Frange","year":"2015","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.idc.2019.05.004_bib64","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1093\/jac\/dky211","article-title":"Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor","volume":"73","author":"Spertilli Raffaelli","year":"2018","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"11","key":"10.1016\/j.idc.2019.05.004_bib65","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1093\/jac\/dkv243","article-title":"Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades","volume":"70","author":"Doyle","year":"2015","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.idc.2019.05.004_bib66","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3851\/IMP2780","article-title":"Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007-2013","volume":"20","author":"Stekler","year":"2015","journal-title":"Antivir Ther"},{"issue":"3","key":"10.1016\/j.idc.2019.05.004_bib67","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/hiv.12414","article-title":"Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom","volume":"18","author":"Tostevin","year":"2017","journal-title":"HIV Med"},{"issue":"3","key":"10.1016\/j.idc.2019.05.004_bib68","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/infdis\/jiw165","article-title":"Successful prevention of transmission of integrase resistance in the Swiss HIV Cohort Study","volume":"214","author":"Scherrer","year":"2016","journal-title":"J\u00a0Infect Dis"},{"issue":"10","key":"10.1016\/j.idc.2019.05.004_bib69","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1093\/jac\/dkv202","article-title":"Primary resistance to integrase strand-transfer inhibitors in Europe","volume":"70","author":"Casadella","year":"2015","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.idc.2019.05.004_bib70","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1089\/aid.2018.0006","article-title":"Prevalence of integrase strand transfer inhibitors resistance mutations in integrase strand transfer inhibitors-Naive and -experienced HIV-1 infected patients: a single center experience","volume":"34","author":"De Francesco","year":"2018","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.idc.2019.05.004_bib71","unstructured":"McClung R, Ocfemia CB, Saduvala N, et\u00a0al. Integrase and Other Transmitted HIV Drug Resistance: 23\u00a0US Jurisdictions, 2013-2016. Conference on Retroviruses and Opportunistic Infections. Seattle, WA, March 4\u20137, 2019."},{"issue":"11","key":"10.1016\/j.idc.2019.05.004_bib72","doi-asserted-by":"crossref","first-page":"ofy294","DOI":"10.1093\/ofid\/ofy294","article-title":"Canary in the coal mine? transmitted mutations conferring resistance to all integrase strand transfer inhibitors in a treatment-naive patient","volume":"5","author":"McGee","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2019.05.004_bib73","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3851\/IMP1749","article-title":"Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient","volume":"16","author":"Boyd","year":"2011","journal-title":"Antivir Ther"},{"issue":"2","key":"10.1016\/j.idc.2019.05.004_bib74","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3851\/IMP1748","article-title":"Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy","volume":"16","author":"Young","year":"2011","journal-title":"Antivir Ther"},{"issue":"6510","key":"10.1016\/j.idc.2019.05.004_bib75","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/373117a0","article-title":"Viral dynamics in human immunodeficiency virus type 1 infection","volume":"373","author":"Wei","year":"1995","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.idc.2019.05.004_bib76","doi-asserted-by":"crossref","first-page":"9864","DOI":"10.1128\/JVI.00915-10","article-title":"Nature, position, and frequency of mutations made in a single cycle of HIV-1 replication","volume":"84","author":"Abram","year":"2010","journal-title":"J\u00a0Virol"},{"issue":"7","key":"10.1016\/j.idc.2019.05.004_bib77","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1086\/368359","article-title":"Prolonged CD4+ cell\/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control","volume":"187","author":"Sufka","year":"2003","journal-title":"J\u00a0Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2019.05.004_bib78","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1128\/JCM.43.3.1395-1400.2005","article-title":"Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation","volume":"43","author":"Weber","year":"2005","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.idc.2019.05.004_bib79","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.meegid.2016.08.031","article-title":"HIV-1 drug resistance and resistance testing","volume":"46","author":"Clutter","year":"2016","journal-title":"Infect Genet Evol"},{"issue":"2","key":"10.1016\/j.idc.2019.05.004_bib80","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/01.aids.0000199825.34241.49","article-title":"Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness","volume":"20","author":"Bangsberg","year":"2006","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.idc.2019.05.004_bib81","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1086\/499364","article-title":"Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study","volume":"42","author":"Ribaudo","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2019.05.004_bib82","doi-asserted-by":"crossref","first-page":"e4724","DOI":"10.1371\/journal.pone.0004724","article-title":"Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update","volume":"4","author":"Bennett","year":"2009","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.idc.2019.05.004_bib83","first-page":"132","article-title":"2017 update of the drug resistance mutations in HIV-1","volume":"24","author":"Wensing","year":"2017","journal-title":"Top Antivir Med"},{"issue":"9","key":"10.1016\/j.idc.2019.05.004_bib84","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11633630-000000000-00000","article-title":"HIV-1 antiretroviral resistance: scientific principles and clinical applications","volume":"72","author":"Tang","year":"2012","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.idc.2019.05.004_bib85","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1086\/378281","article-title":"Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates","volume":"188","author":"Whitcomb","year":"2003","journal-title":"J\u00a0Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2019.05.004_bib86","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1086\/430709","article-title":"Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection","volume":"41","author":"Campbell","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.idc.2019.05.004_bib87","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1128\/JVI.76.7.3248-3256.2002","article-title":"The M184V mutation reduces the selective excision of zidovudine 5'-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1","volume":"76","author":"Boyer","year":"2002","journal-title":"J\u00a0Virol"},{"issue":"12","key":"10.1016\/j.idc.2019.05.004_bib88","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1097\/01.aids.0000131355.44834.e4","article-title":"Phenotypic impact of HIV reverse transcriptase M184I\/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance","volume":"18","author":"Ross","year":"2004","journal-title":"AIDS"},{"issue":"9581","key":"10.1016\/j.idc.2019.05.004_bib89","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)61047-2","article-title":"Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial","volume":"370","author":"Madruga","year":"2007","journal-title":"Lancet"},{"issue":"9581","key":"10.1016\/j.idc.2019.05.004_bib90","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(07)61048-4","article-title":"Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial","volume":"370","author":"Lazzarin","year":"2007","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.idc.2019.05.004_bib91","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/15284336.2015.1115585","article-title":"Clinical outcomes of virologically-suppressed patients with pre-existing HIV-1 drug resistance mutations switching to rilpivirine\/emtricitabine\/tenofovir disoproxil fumarate in the SPIRIT Study","volume":"17","author":"Porter","year":"2016","journal-title":"HIV Clin Trials"},{"issue":"3","key":"10.1016\/j.idc.2019.05.004_bib92","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1128\/AAC.02403-13","article-title":"In\u00a0vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor","volume":"58","author":"Lai","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idc.2019.05.004_bib93","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3851\/IMP1719","article-title":"Virological characterization of patients failing darunavir\/ritonavir or lopinavir\/ritonavir treatment in the ARTEMIS study: 96-week analysis","volume":"16","author":"Lathouwers","year":"2011","journal-title":"Antivir Ther"},{"issue":"12","key":"10.1016\/j.idc.2019.05.004_bib94","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1093\/cid\/cix1108","article-title":"Effectiveness of protease inhibitor\/nucleos(t)ide reverse transcriptase inhibitor-based second-line antiretroviral therapy for the treatment of human immunodeficiency virus type 1 infection in Sub-Saharan Africa: a systematic review and meta-analysis","volume":"66","author":"Stockdale","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2019.05.004_bib95","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/QAD.0b013e328013d9d7","article-title":"Efficacy and safety of TMC114\/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1","volume":"21","author":"Katlama","year":"2007","journal-title":"AIDS"},{"issue":"6","key":"10.1016\/j.idc.2019.05.004_bib96","doi-asserted-by":"crossref","first-page":"F11","DOI":"10.1097\/QAD.0b013e3280b07b47","article-title":"Week 24 efficacy and safety of TMC114\/ritonavir in treatment-experienced HIV patients","volume":"21","author":"Haubrich","year":"2007","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.idc.2019.05.004_bib97","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/QAI.0b013e3181359cfb","article-title":"Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3","volume":"46","author":"Molina","year":"2007","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"13","key":"10.1016\/j.idc.2019.05.004_bib98","doi-asserted-by":"crossref","first-page":"7249","DOI":"10.1128\/JVI.06618-11","article-title":"Substitutions at amino acid positions 143, 148, and 155 of HIV-1 integrase define distinct genetic barriers to raltegravir resistance in\u00a0vivo","volume":"86","author":"Fransen","year":"2012","journal-title":"J\u00a0Virol"},{"issue":"6","key":"10.1016\/j.idc.2019.05.004_bib99","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1128\/AAC.02568-12","article-title":"Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness","volume":"57","author":"Abram","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.idc.2019.05.004_bib100","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/infdis\/jiu051","article-title":"Dolutegravir in antiretroviral-experienced patients with raltegravir- and\/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study","volume":"210","author":"Castagna","year":"2014","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.idc.2019.05.004_bib101","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciy1132","article-title":"Dolutegravir monotherapy versus dolutegravir\/abacavir\/lamivudine for virologically suppressed people living with chronic HIV infection: the randomized non-inferiority MONCAY trial","author":"Hocqueloux","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.idc.2019.05.004_bib102","doi-asserted-by":"crossref","first-page":"e547","DOI":"10.1016\/S2352-3018(17)30152-2","article-title":"Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial","volume":"4","author":"Wijting","year":"2017","journal-title":"Lancet HIV"},{"issue":"9893","key":"10.1016\/j.idc.2019.05.004_bib103","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","article-title":"Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study","volume":"382","author":"Cahn","year":"2013","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.idc.2019.05.004_bib104","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/infdis\/jiy175","article-title":"The S230R integrase substitution associated with virus load rebound during dolutegravir monotherapy confers low-level resistance to integrase strand-transfer inhibitors","volume":"218","author":"Pham","year":"2018","journal-title":"J\u00a0Infect Dis"},{"issue":"7","key":"10.1016\/j.idc.2019.05.004_bib105","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/jac\/dkw071","article-title":"Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors","volume":"71","author":"Brenner","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"12","key":"10.1016\/j.idc.2019.05.004_bib106","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1128\/AAC.01474-16","article-title":"Antiviral activity of Bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile","volume":"60","author":"Tsiang","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.idc.2019.05.004_bib107","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1016\/S2352-3018(17)30065-6","article-title":"Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial","volume":"4","author":"Paton","year":"2017","journal-title":"Lancet HIV"},{"issue":"2","key":"10.1016\/j.idc.2019.05.004_bib108","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S2352-3018(14)00061-7","article-title":"Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis","volume":"2","author":"Boyd","year":"2015","journal-title":"Lancet HIV"},{"issue":"7","key":"10.1016\/j.idc.2019.05.004_bib109","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/hiv.12024","article-title":"Subgroup analysis of virological response rates with once- and twice-daily darunavir\/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial","volume":"14","author":"Sension","year":"2013","journal-title":"HIV Med"},{"issue":"3","key":"10.1016\/j.idc.2019.05.004_bib110","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1056\/NEJMoa1311274","article-title":"Assessment of second-line antiretroviral regimens for HIV therapy in Africa","volume":"371","author":"Paton","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.idc.2019.05.004_bib111","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/00042560-200001010-00004","article-title":"Emergence of dual resistance to zidovudine and lamivudine in HIV-1-infected patients treated with zidovudine plus lamivudine as initial therapy","volume":"23","author":"Kuritzkes","year":"2000","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"11","key":"10.1016\/j.idc.2019.05.004_bib112","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1097\/01.inf.0000243211.36690.d5","article-title":"Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy","volume":"25","author":"Averbuch","year":"2006","journal-title":"Pediatr Infect Dis J"},{"issue":"11","key":"10.1016\/j.idc.2019.05.004_bib113","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1097\/QAD.0b013e3281ac229b","article-title":"Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase","volume":"21","author":"Parikh","year":"2007","journal-title":"AIDS"},{"issue":"7","key":"10.1016\/j.idc.2019.05.004_bib114","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3851\/IMP2443","article-title":"A\u00a0randomized comparison of second-line lopinavir\/ritonavir monotherapy versus tenofovir\/lamivudine\/lopinavir\/ritonavir in patients failing NNRTI regimens: the HIV STAR study","volume":"17","author":"Bunupuradah","year":"2012","journal-title":"Antivir Ther"},{"issue":"9883","key":"10.1016\/j.idc.2019.05.004_bib115","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/S0140-6736(13)61164-2","volume":"381","author":"Boyd","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.idc.2019.05.004_bib116","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1016\/S2352-3018(16)30011-X","article-title":"Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study","volume":"3","author":"La Rosa","year":"2016","journal-title":"Lancet HIV"},{"key":"10.1016\/j.idc.2019.05.004_bib117","unstructured":"Aboud M, Kaplan R, Lombaard J, et\u00a0al. Superior efficacy of dolutegravir (DTG) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) compared with lopinavir\/ritonavir (LPV\/RTV) plus 2 NRTIs in second-line treatment: interim data from the DAWNING study. 9th IAS Conference on HIV Science. Paris, France, July 25, 2017."},{"issue":"5","key":"10.1016\/j.idc.2019.05.004_bib118","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/infdis\/jis750","article-title":"Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study","volume":"207","author":"Eron","year":"2013","journal-title":"J\u00a0Infect Dis"},{"issue":"12","key":"10.1016\/j.idc.2019.05.004_bib119","doi-asserted-by":"crossref","first-page":"908","DOI":"10.7326\/M15-0949","article-title":"HIV salvage therapy does not require nucleoside reverse transcriptase inhibitors: a randomized, controlled trial","volume":"163","author":"Tashima","year":"2015","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.idc.2019.05.004_bib120","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1086\/508353","article-title":"Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial","volume":"43","author":"Gathe","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.idc.2019.05.004_bib121","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1086\/508352","article-title":"Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial","volume":"43","author":"Cahn","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"9581","key":"10.1016\/j.idc.2019.05.004_bib122","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(07)61049-6","article-title":"Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48\u00a0weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial","volume":"370","author":"Madruga","year":"2007","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.idc.2019.05.004_bib123","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/QAD.0b013e328345ee95","article-title":"Week 48 analysis of once-daily vs. twice-daily darunavir\/ritonavir in treatment-experienced HIV-1-infected patients","volume":"25","author":"Cahn","year":"2011","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.idc.2019.05.004_bib124","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMoa0708975","article-title":"Raltegravir with optimized background therapy for resistant HIV-1 infection","volume":"359","author":"Steigbigel","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.idc.2019.05.004_bib125","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1473-3099(11)70249-3","article-title":"Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study","volume":"12","author":"Molina","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"22","key":"10.1016\/j.idc.2019.05.004_bib126","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1056\/NEJMoa035026","article-title":"Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America","volume":"348","author":"Lalezari","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.idc.2019.05.004_bib127","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1056\/NEJMoa035211","article-title":"Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia","volume":"348","author":"Lazzarin","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.idc.2019.05.004_bib128","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa0803152","article-title":"Maraviroc for previously treated patients with R5 HIV-1 infection","volume":"359","author":"Gulick","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.idc.2019.05.004_bib129","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1086\/598965","article-title":"A\u00a0double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1","volume":"199","author":"Saag","year":"2009","journal-title":"J\u00a0Infect Dis"},{"issue":"9","key":"10.1016\/j.idc.2019.05.004_bib130","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/630210","article-title":"High rate of virologic suppression with raltegravir plus etravirine and darunavir\/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial","volume":"49","author":"Yazdanpanah","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2019.05.004_bib131","unstructured":"Grinsztejn B, Hughes M, Ritz J, et\u00a0al. Results of ACTG A5288: a strategy study in RLS for 3rd-line ART candidates. Conference on Retroviruses and Opportunistic Infections. Boston, MA, March 4\u20137, 2018."},{"issue":"7","key":"10.1016\/j.idc.2019.05.004_bib132","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa1711460","article-title":"Phase 3 study of ibalizumab for multidrug-resistant HIV-1","volume":"379","author":"Emu","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.idc.2019.05.004_bib133","first-page":"127","article-title":"Investigational antiretroviral drugs: what is coming down the pipeline","volume":"25","author":"Gulick","year":"2018","journal-title":"Top Antivir Med"},{"issue":"10","key":"10.1016\/j.idc.2019.05.004_bib134","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.chembiol.2018.07.014","article-title":"The high genetic barrier of EFdA\/MK-8591 stems from strong interactions with the active site of drug-resistant HIV-1 reverse transcriptase","volume":"25","author":"Takamatsu","year":"2018","journal-title":"Cell Chem Biol"},{"issue":"1","key":"10.1016\/j.idc.2019.05.004_bib135","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/QAI.0000000000001304","article-title":"The second-generation maturation inhibitor GSK3532795 maintains potent activity toward HIV protease inhibitor-resistant clinical isolates","volume":"75","author":"Ray","year":"2017","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"10","key":"10.1016\/j.idc.2019.05.004_bib136","doi-asserted-by":"crossref","first-page":"e427","DOI":"10.1016\/S2352-3018(15)00177-0","article-title":"Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24\u00a0week results of AI438011, a phase 2b, randomised controlled trial","volume":"2","author":"Lalezari","year":"2015","journal-title":"Lancet HIV"},{"key":"10.1016\/j.idc.2019.05.004_bib137","series-title":"Consolidated guidelines on the Use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach","author":"World Health Organization","year":"2016"},{"issue":"10","key":"10.1016\/j.idc.2019.05.004_bib138","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1056\/NEJMc1807653","article-title":"Neural-tube defects with dolutegravir treatment from the time of conception","volume":"379","author":"Zash","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.idc.2019.05.004_bib139","series-title":"Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents","year":"2017"},{"issue":"8","key":"10.1016\/j.idc.2019.05.004_bib140","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1001\/archinte.144.8.1667","article-title":"Rifampin drug interactions","volume":"144","author":"Baciewicz","year":"1984","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.idc.2019.05.004_bib142","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1185\/03007995.2012.747952","article-title":"Update on rifampin, rifabutin, and rifapentine drug interactions","volume":"29","author":"Baciewicz","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.idc.2019.05.004_bib143","unstructured":"Cerrone M, Alfarisi O, Neary M, et\u00a0al. Rifampin effect on tenofovir alafenamide (TAF) plasma\/intracellular pharmacokinetics. Conference on Retroviruses and Opportunistic Infections. Boston, MA, March 4\u20137, 2018."},{"issue":"7","key":"10.1016\/j.idc.2019.05.004_bib144","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s40261-017-0513-4","article-title":"The effect of single and multiple doses of rifampin on the pharmacokinetics of doravirine in healthy subjects","volume":"37","author":"Yee","year":"2017","journal-title":"Clin Drug Investig"},{"issue":"1","key":"10.1016\/j.idc.2019.05.004_bib145","doi-asserted-by":"crossref","first-page":"e84866","DOI":"10.1371\/journal.pone.0084866","article-title":"Randomised pharmacokinetic trial of rifabutin with lopinavir\/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam","volume":"9","author":"Lan","year":"2014","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.idc.2019.05.004_bib146","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1128\/AAC.01749-09","article-title":"Pharmacokinetics of darunavir\/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers","volume":"54","author":"Sekar","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.idc.2019.05.004_bib147","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1128\/AAC.48.5.1553-1560.2004","article-title":"Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers","volume":"48","author":"la Porte","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.idc.2019.05.004_bib148","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1128\/AAC.01598-10","article-title":"Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets","volume":"55","author":"Decloedt","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.idc.2019.05.004_bib149","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1097\/QAD.0b013e3282faa71e","article-title":"High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir\/ritonavir tablets","volume":"22","author":"Nijland","year":"2008","journal-title":"AIDS"},{"issue":"9","key":"10.1016\/j.idc.2019.05.004_bib150","doi-asserted-by":"crossref","first-page":"e44793","DOI":"10.1371\/journal.pone.0044793","article-title":"Coadministration of lopinavir\/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa","volume":"7","author":"Murphy","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.idc.2019.05.004_bib151","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/QAI.0b013e318276cda9","article-title":"Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects","volume":"62","author":"Dooley","year":"2013","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.idc.2019.05.004_bib152","unstructured":"Dooley KE, Kaplan R, Mwelase N, et\u00a0al. Safety and efficacy of dolutegravir-based ART in TB\/HIV coinfected adults at week 24. Conference on Retroviruses and Opportunistic Infections. Boston, MA, March 4\u20137, 2018."},{"issue":"7","key":"10.1016\/j.idc.2019.05.004_bib153","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1128\/AAC.01468-08","article-title":"Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir","volume":"53","author":"Wenning","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.idc.2019.05.004_bib154","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1177\/0091270010375959","article-title":"Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: in\u00a0vitro\/in\u00a0vivo correlation","volume":"51","author":"Brainard","year":"2011","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.idc.2019.05.004_bib155","unstructured":"Custodio JM, West SK, Collins S, et\u00a0al. Pharmacokinetics of bictegravir administered twice daily in combination with rifampin. Conference on Retroviruses and Opportunistic Infections. Boston, MA, March 4\u20137, 2018."},{"issue":"6","key":"10.1016\/j.idc.2019.05.004_bib156","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1086\/319368","article-title":"Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens","volume":"32","author":"Hoff","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2019.05.004_bib157","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1097\/01.aids.0000218550.85081.59","article-title":"Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy","volume":"20","author":"Matthews","year":"2006","journal-title":"AIDS"},{"issue":"5","key":"10.1016\/j.idc.2019.05.004_bib158","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/hep.510300525","article-title":"Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients","volume":"30","author":"Benhamou","year":"1999","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.idc.2019.05.004_bib159","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1056\/NEJM200301093480218","article-title":"Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus","volume":"348","author":"Benhamou","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.idc.2019.05.004_bib160","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1086\/380398","article-title":"Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus","volume":"189","author":"Dore","year":"2004","journal-title":"J\u00a0Infect Dis"},{"issue":"17","key":"10.1016\/j.idc.2019.05.004_bib161","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1097\/00002030-200211220-00023","article-title":"Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine","volume":"16","author":"Nunez","year":"2002","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.idc.2019.05.004_bib162","doi-asserted-by":"crossref","first-page":"F7","DOI":"10.1097\/00002030-200301030-00002","article-title":"An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals","volume":"17","author":"Nelson","year":"2003","journal-title":"AIDS"},{"issue":"12","key":"10.1016\/j.idc.2019.05.004_bib163","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1086\/345770","article-title":"Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus\/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed","volume":"186","author":"Ristig","year":"2002","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.idc.2019.05.004_bib164","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12876-015-0308-0","article-title":"HBV genotypes and response to tenofovir disoproxil fumarate in HIV\/HBV-coinfected persons","volume":"15","author":"Bihl","year":"2015","journal-title":"BMC Gastroenterol"},{"issue":"6","key":"10.1016\/j.idc.2019.05.004_bib165","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/QAD.0b013e328334bddb","article-title":"Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption","volume":"24","author":"Dore","year":"2010","journal-title":"AIDS"},{"issue":"8","key":"10.1016\/j.idc.2019.05.004_bib166","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1124\/dmd.117.079038","article-title":"The drug-drug interaction potential of antiviral agents for the treatment of chronic hepatitis C infection","volume":"46","author":"Garrison","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.idc.2019.05.004_bib169","series-title":"HEP drug interactions","year":"2019"},{"issue":"5","key":"10.1016\/j.idc.2019.05.004_bib170","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1097\/00126334-200412150-00001","article-title":"Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups","volume":"37","author":"Tuaillon","year":"2004","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"3","key":"10.1016\/j.idc.2019.05.004_bib171","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1089\/088922204322996590","article-title":"Are fusion inhibitors active against all HIV variants?","volume":"20","author":"Poveda","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"4","key":"10.1016\/j.idc.2019.05.004_bib172","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1128\/AAC.01284-07","article-title":"In\u00a0vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors","volume":"52","author":"Desbois","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.idc.2019.05.004_bib173","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1747-0285.2008.00647.x","article-title":"Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use","volume":"71","author":"Brower","year":"2008","journal-title":"Chem Biol Drug Des"},{"issue":"10","key":"10.1016\/j.idc.2019.05.004_bib174","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/cid\/civ124","article-title":"Dolutegravir in HIV-2-infected patients with resistant virus to first-line integrase inhibitors from the French named patient program","volume":"60","author":"Descamps","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2019.05.004_bib175","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/jac\/dkn335","article-title":"HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in\u00a0vitro","volume":"62","author":"Roquebert","year":"2008","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.idc.2019.05.004_bib176","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1089\/aid.2007.0303","article-title":"Genetic diversity of integrase (IN) sequences in antiretroviral treatment-naive and treatment-experienced HIV type 2 patients","volume":"24","author":"Xu","year":"2008","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.idc.2019.05.004_bib177","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12977-015-0146-8","article-title":"In\u00a0vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2","volume":"12","author":"Smith","year":"2015","journal-title":"Retrovirology"},{"key":"10.1016\/j.idc.2019.05.004_bib178","article-title":"A\u00a0new mechanism of resistance of HIV-2 to integrase inhibitors: a 5 amino-acids insertion in the integrase C-terminal domain","author":"Le Hingrat","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2019.05.004_bib179","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1742-4690-8-68","article-title":"G140S\/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not","volume":"8","author":"Ni","year":"2011","journal-title":"Retrovirology"},{"issue":"1","key":"10.1016\/j.idc.2019.05.004_bib180","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1128\/AAC.05313-11","article-title":"In\u00a0vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors","volume":"56","author":"Visseaux","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2019.05.004_bib181","series-title":"Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendation on early infant diagnosis of HIV","author":"World Health Organization","year":"2018"},{"issue":"16","key":"10.1016\/j.idc.2019.05.004_bib182","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1001\/archinte.167.16.1782","article-title":"Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types","volume":"167","author":"von Wyl","year":"2007","journal-title":"Arch Intern Med"},{"issue":"19","key":"10.1016\/j.idc.2019.05.004_bib183","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.idc.2019.05.004_bib184","doi-asserted-by":"crossref","first-page":"776","DOI":"10.4102\/sajhivmed.v18i1.776","article-title":"Adult antiretroviral therapy guidelines 2017","volume":"18","author":"Meintjes","year":"2017","journal-title":"South Afr J HIV Med"},{"key":"10.1016\/j.idc.2019.05.004_bib185","article-title":"Consolidated guidelines for prevention and treatment of HIV in Uganda","year":"2018"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552019300406?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552019300406?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:15:56Z","timestamp":1760195756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552019300406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":181,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0891552019300406"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2019.05.004","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Virologic Failure and HIV Drug Resistance","name":"articletitle","label":"Article Title"},{"value":"Infectious Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idc.2019.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}